Compare PRA & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRA | BHVN |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.6B |
| IPO Year | 2000 | 2022 |
| Metric | PRA | BHVN |
|---|---|---|
| Price | $24.51 | $9.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $25.00 | ★ $28.85 |
| AVG Volume (30 Days) | 572.3K | ★ 1.9M |
| Earning Date | 05-25-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $1,098,028,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.30 | $7.48 |
| 52 Week High | $24.77 | $31.18 |
| Indicator | PRA | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 38.12 |
| Support Level | $23.88 | $9.32 |
| Resistance Level | $24.64 | $10.28 |
| Average True Range (ATR) | 0.12 | 0.71 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 28.00 | 16.67 |
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.